206751-75-9

Usage

Uses

Used in Organic Synthesis:
α-Benzyloxycyclobutanone is utilized as a building block for the synthesis of complex organic molecules, leveraging its reactivity to undergo multiple transformations, which is crucial for creating a diverse range of chemical products.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, α-benzyloxycyclobutanone serves as an intermediate in the production of various fine chemicals and active pharmaceutical ingredients, contributing to the development of new medications and therapeutic agents.
Used in Agrochemical Industry:
Similarly, in the agrochemical industry, α-benzyloxycyclobutanone is employed as an intermediate for synthesizing a range of agrochemicals, including pesticides and other crop protection products, enhancing agricultural productivity and crop protection.
Used in Academic Research:
α-Benzyloxycyclobutanone is also used as a substrate in academic research for studying organic chemistry, providing insights into reaction mechanisms and the development of new synthetic methodologies, which can lead to more efficient and sustainable chemical processes.

Upstream product

• 99440-99-0 2-hydroxycyclobutanone 
• 100-51-6 benzyl alcohol 
• 100-39-0 benzyl bromide 
• 17082-61-0 1,2-bis(trimethylsiloxy)cyclobutene 

Downstream Products

• 905916-00-9 (1R,2R,1'S)-2-benzyloxy-1-[(1'-phenylethyl)amino]cyclobutanecarbonitrile 
• 905916-02-1 (1R,2S,1'S)-2-benzyloxy-1-[(1'-phenylethyl)amino]cyclobutanecarbonitrile 
• 905916-03-2 (1S,2R,1'S)-2-benzyloxy-1-[(1'-phenylethyl)amino]cyclobutanecarbonitrile 
• 905916-01-0 (1S,2S,1'S)-2-benzyloxy-1-[(1'-phenylethyl)amino]cyclobutanecarbonitrile 

Relevant academic research and scientific papers

Synthesis and biological evaluation of anti-1-amino-2-[18F]fluoro-cyclobutyl-1-carboxylic acid (anti-2-[18F]FACBC) in rat 9L gliosarcoma

A new [18F] labeled amino acid anti-1-amino-2-[18F]fluoro-cyclobutyl-1-carboxylic acid 9 (anti-2-[18F]FACBC) was synthesized in 30% decay-corrected yield with high radiochemical purity over 99%. The cyclic sulfamidate precursor was very stable and highly reactive towards nucleophilic radiofluorination. Cell uptake assays with rat 9L gliosarcoma cells showed that [18F]9 was transported into tumor cells via multiple amino acid transport systems, including L and A systems. Biodistribution study in rats with intracranial 9L gliosarcoma tumors demonstrated that [18F]9 had a rapid and prolonged accumulation in tumors with 26:1 tumor to brain ratio at 120 min post-injection. In this model, [18F]9 is a potential PET tracer for brain tumor imaging.

7-, 8-, and 10-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE

In its many embodiments, the present invention provides certain 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives of Formula (I): or a pharmaceutically acceptable salt thereof, wherein ring A, R1, R2, and R4 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutic agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE

Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

TDO2 INHIBITORS

Presently provided are inhibitors of cellularly expressed TDO2 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.

Acid-catalyzed reaction of 2-hydroxycyclobutanone with benzylic alcohols

The acid-promoted syntheses of 2-(benzyloxy)cyclobutanones and bis(benzyloxy)dioxatricyclo decanes were achieved starting from 2-hydroxycyclobutanone and variously functionalized benzyl alcohols. The reaction sequences afforded the desired products in good to high yields and in a solvent-dependent chemoselective fashion.

Stereoselective synthesis of (1R,2R)-1-amino-2-hydroxycyclobutanecarboxylic acid-serine derivative-, from racemic or optically active 2-benzyloxycyclobutanone

An easy and efficient one-pot reaction from readily available 2-benzyloxycyclobutanone gave, by means of an asymmetric Strecker synthesis, a kinetic or thermodynamic nitrile with good selectivity. After separation, the major trans-amino nitrile underwent basic hydrolysis and hydrogenolysis, followed by acidic hydrolysis, to give optically active (1R,2R)-1-amino-2-hydroxycyclobutanecarboxylic acid, serine derivative. The absolute configuration has been established by X-ray analysis of the corresponding cis-amino nitrile.

Diastereo- and Enantioselective Synthesis of (+)- and (-)-cis-2-Aminocyclobutanols

The hitherto unknown (+)- and (-)-cis-2-aminocyclobutanols 6a,b and 7a,b, as well as the corresponding benzyloxycyclobutanamines 8a,b, have been synthesized by means of asymmetric reductive amination, with de values of 100percent and ee values ranging from 96.9 to 99.8percent. The relative cis configuration has been established by NO experiments, whereas the absolute stereochemistry has been deduced from the CD spectra of the corresponding salicylidene derivatives and confirms the like induction at C-1.